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With the increasing excitement around new immu-
notherapeutic approaches, there has been a shift in the
way viral cancer therapy is regarded from providing
mainly oncolysis towards being a cancer immunotherapy.
Adenoviruses have a unique ability to prime and boost
immune responses. GM-CSF coding adenovirus
ONCOS-102 causes immunogenic cancer cell death
whereupon tumor antigens are presented into the immu-
nogenic environment. ONCOS-102 has been previously
shown to initiate CD8+ T cell responses against tumor-
derived antigens in chemotherapy refractory cancer
patients.
A total of 12 cancer patients were treated with
repeated intratumoral injections of ONCOS-102 in a
Phase I study. Sequential biopsies were collected at
baseline and 1 and 2 months after treatment initiation
and analyzed for the presence of immune cells by
immunohistochemistry (IHC) in digitally scanned sam-
ples. Readout of the expression levels for innate immune
cells (CD68, CD163, CD11c), T cells (CD3, CD4, CD8),
and B cells (CD19) was performed in tumorous regions
by the use of an image analysis algorithm based on
color deconvolution and segmentation of the IHC
stained cells. In an exploratory analysis, correlation
between absolute expression levels of different immune
cell markers in tumors and overall survival (OS) was
assessed by Spearman´s rank correlation analysis.
At baseline, the absolute expression level of macro-
phage marker CD68 negatively correlated with OS (cor-
relation coefficient (r)= -0.59, p=0.04), suggesting that
tumor-associated macrophages (TAMs) in untreated
tumors were tumorigenic. No correlation between other
immune cell markers and OS was seen at baseline. 11/12
patients showed a post-treatment increase in tumor-infil-
trating innate and adaptive immune cells, with the most
prominent increase seen in CD8+ cells. In contrast to
baseline, post-treatment samples showed a positive corre-
lation between the expression level of CD68+ cells and
OS (r=0.71, p=0.01), suggesting that CD68+ macrophages
that were attracted into tumors after ONCOS-102 injec-
tion displayed different functionality than TAMs present
prior to treatment. Furthermore, absolute expression
levels of T cell markers CD3 (r=0.74, p=0.006), CD4
(r=0.76, p=0.004), and CD8 (r=0.73, p=0.007) in post-
treatment biopsies all positively correlated with OS.
To summarize, ONCOS-102 induced infiltration of
CD68+ macrophages and T cells which was associated
with increased OS, while CD68+ TAMs pre-treatment
was associated with shortened OS. This suggest that local
immunotherapy with ONCOS-102 has the potential to
activate immunologically silent tumors and reduce local
immune suppression in advanced tumors.
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